Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei - 02/09/11
Abstract |
Background: Many centers include intraperitoneal chemotherapy for treatment of pseudomyxoma peritonei. This study documented the morbidity of intraperitoneal chemotherapy in a single institution.
Methods: A retrospective review of pseudomyxoma peritonei over a 6-year period was undertaken. Treatment, morbidity, and outcome were documented.
Results: Eleven patients were identified with an average of 1.9 debulking procedures and 0.8 chemotherapy courses (0.3 complete). Intraperitoneal chemotherapy was not completed in 5 patients because of complications (56%): severe abdominal pain, seizure, neutropenia, and thrombocytopenia (the latter resulted in 1 patient’s death). There was no association between incomplete chemotherapy and recurrence. Recurrence was 64% in those without chemotherapy and 44% in those with. Follow-up averaged 26 months and actual 3-year survival was 60%.
Conclusions: Intraperitoneal chemotherapeutic morbidity and mortality were 56% and 11%, respectively. Chemotherapy was associated with decreased recurrence. To optimize outcomes, multicenter prospective trials will likely be required to further refine intraperitoneal chemotherapy protocols.
Le texte complet de cet article est disponible en PDF.Keywords : Pseudomyxoma peritonei, Intraperitoneal chemotherapy, Morbidity, Dihydropyrimidine dehydrogenase deficiency, Mitomycin C, 5-Fluorouracil
Plan
Vol 183 - N° 5
P. 529-532 - mai 2002 Retour au numéro
Article précédent
- Surgical management of acute sigmoid diverticulitis
- N.P. Blair, E. Germann
- An institutional experience with laparoscopic gastric bypass complications seen in the first year compared with open gastric bypass complications during the same period
- Craig See, Preston L Carter, David Elliott, Philip Mullenix, William Eggebroten, Clifford Porter, David Watts
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?